Personalized and Precision Medicine Journal

Abstract Introduction: MicroRNA-124 (miR-124) is moderated in some human malignancies and is associated with tumor advancement. But, its expression and clinical importance in ovarian carcinoma is still unclear. Thus, the goal of this study was to feature the clinical importance of personalized miR-124 expression in ovarian carcinoma. Methods: 94 women ovarian cancer tissues and 26 normal ovarian tissues were accumulated from patients. We used Real-time PCR to quantify the expression of personalized miR-124 in clinical ovarian carcinoma specimen and normal tissues. Moreover, we measured the miR-124 relationship with clinicopathologic characteristics and the ovarian carcinoma survival. Results: The lesser expression of miR-124 in tumor tissues can be found in compared with normal tissue using PCR method (P < 0.05). Our data exhibited that there is a notable association among low expression of miR-12 and clinical staging of ovarian carcinoma (P = 0.023). Nevertheless, miR-124 expression was not notably associated with age (P = 0. 671), differentiation status (P = 0.512), lymph node metastasis (P = 0.415) and histological subtypes (0.547). Kaplan-Meier survival analysis and log-rank test were applied in present study. These tests showed the less expression on patients had markedly short-term survival time in comparison with high expression group (P = 0.022). Multivariate Cox proportional hazards model analysis revealed that less expression of miR-124 and clinical staging were contribute to short-term survival in patients with ovarian carcinoma. The HR of the low miR-124 expression group was calculated to be 2.532 (95% CI: 1.572-9.237, P = 0.021), (clinical staging HR: 2.532; 95% CI: 1.321-9.241, P = 0.032).
Conclusions: These findings suggested that personalized miR-124 could be considered as an independent prognostic factor for ovarian carcinoma patients. Our findings suggested that low expression of personalized miR-124 has prognostic worthiness in ovarian.

Abstract Introduction: Nigella sativa (NS) is a widely used medicinal plant and appears to have a general health protective effect. As has been reported previously, pharmacological actions of NS have been explored including antidiabetic, anticancer, immunomodilative, analgesic, anti-inflammatory, spasmolytic, bronchodilator, hepatoprotective, renal protective, antioxidant properties, gastroprotective, antihistaminic, antibacterial, neuroprotective and antioxidative effects and etc. Methods: The present review aimed to give a personalized care for patients using detailed survey of the literature on and neuroprotective activities of the plant. Pubmed, Science Direct, Google scholar and Springer databases were searched from 1983 till January 2015. Key words were included: N. sativa, black seed, neuropathy, neuroprotective, brain and spinal injury, thymoquinone and posttrauma. Searching was limited to articles with English language. Review articles, case reports, abstract in symposium and congress, studies on N. sativa mixed with other plants were excluded. This study thus launches a huge resource for understanding the role of NS in in brain and spinal cord tissue damage after trauma with broad relevance for personalized medicine. Results: Results indicated that based on personalized medicine many of the herbal attributes of the herbal are due to the thymoquinone presence as its bioactive component, and therapy with NS notably decreased post-traumatic degenerative neurons and distorted nerve cells were not primarily treated in NS rats. In conclusion, NS can improve neuropathic status and neurological dysfunctions in the brain and spinal injury models. However, more clinical trials are necessary to clarify beneficial effects of NS its effective type and dosage for neuropathies management and its complications. Conclusions: Finally, NS treatment might be effective in detrimental the cerebral and spinal cord after trauma as personalized care for patients, and therefore shows potential for clinical implications.